BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers

BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, recently announced that it will collaborate with Celgene Cellular Therapeutics (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision’s proprietary ThawSTARÔ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

BioCision, LLC, a leader in advanced technology to improve biological sample handling and standardization, recently announced that it will collaborate with Celgene Cellular Therapeutics (a subsidiary of Celgene Corporation), to accelerate the development of a cell thawing solution based on BioCision’s proprietary ThawSTARÔ technology for the 6 mL injectable vial that CCT has chosen to store PDA-002, a cryopreserved, allogeneic cell therapy currently in clinical development to treat diabetic foot ulcers in patients with peripheral arterial disease.

Read More:
BioCision, CCT to develop ThawSTAR automated cell thawing system for treatment of diabetic foot ulcers